Get the Stockscreener App
862.86
2.17%
18.36
After Hours:
864.45
1.59
+0.18%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $862.86, with a volume of 5.01M.
It is up +2.17% in the last 24 hours and up +13.09% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$844.50
Open:
$839.16
24h Volume:
5.01M
Relative Volume:
1.12
Market Cap:
$816.66B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
42.67
EPS:
20.2197
Net Cash Flow:
$-50.20M
1W Performance:
+4.53%
1M Performance:
+13.09%
6M Performance:
-4.01%
1Y Performance:
+3.99%
1-Day Range:
$834.19
$869.91
1-Week Range:
$809.63
$869.91
52-Week Range:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Surges on Strong Q3 Results and Upgraded 2025 Ou - GuruFocus
Should You Buy Viking Therapeutics Before Nov. 5? - The Motley Fool
Why The Story Around Eli Lilly Is Evolving After Recent Analyst Updates and Company News - Yahoo! Finance UK
Eli Lilly and Company Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next - Yahoo Finance
Eli Lilly and Company $LLY Shares Acquired by Tredje AP fonden - MarketBeat
A Look at Eli Lilly’s (LLY) Valuation After Strong Q3 Earnings, Upbeat Guidance, and Zepbound Expansion Plans - simplywall.st
Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer - MSN
Eli Lilly To Invest Over $1.2 Billion In Puerto Rico Expansion To Boost U.S. Oral Medicine Manufacturing - Pulse 2.0
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $976 to $1,069 - 富途牛牛
Why Eli Lilly Stock Rose Almost 5% Last Week? - TIKR.com
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points - Investor's Business Daily
Eli Lilly Reports Strong Q3 2025 Growth - The Globe and Mail
Eli Lilly’s Earnings Call: Robust Growth and Strategic Wins - TipRanks
AstraZeneca, Eli Lilly, Merck commit $120M to Virginia pharma training - Virginia Business
Eli Lilly and Company (NYSE:LLY) Trading 2.2% Higher on Strong Earnings - MarketBeat
Evaluating Eli Lilly (LLY): Is the Pharma Giant’s Recent Growth Reflected in Its Current Valuation? - Yahoo Finance
Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval - TipRanks
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report - Pharmaceutical Executive
IU-Lilly study to explore drugs’ impact on job productivity - Indianapolis Business Journal
Argus Raises Eli Lilly's Price Target to $930 From $900 - MarketScreener
Why Eli Lilly is making weight-loss pills before regulatory approval - Yahoo! Finance UK
Eli Lilly's Diabetes, Obesity Drugs Drive Strong Q3 Beat, BofA Securities Says - MarketScreener
Eli Lilly’s Weight-Loss Drugs Set New Sales Records - Finimize
Lilly quietly cuts a pain drug from its pipeline - BioPharma Dive
Eli Lilly Tops Expectations With Blockbuster Obesity And Diabetes Sales - Finimize
Eli Lilly price target raised to $950 from $900 at BofA - TipRanks
Eli Lilly Earnings: International Tirzepatide Sales Outpaced Our Expectations - Morningstar
Eli Lilly is Building a Formidable Portfolio and Pipeline in Cardiometabolic Disease - Morningstar
Eli Lilly's Solid Q3 Highlights Strong Mounjaro Demand; Orforglipron Launch in 2026 Seen as Growth Driver, Morgan Stanley Says - MarketScreener
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings (NYSE:LLY) - Seeking Alpha
LLY Analyst Rating Update: Cantor Fitzgerald Raises Price Target - GuruFocus
Eli Lilly expands sports-health partnerships with eczema awareness, official 2026 Winter Olympics partner - PRWeek
Eli Lilly says weight-loss pill a candidate for speedy approval under new US program - Reuters
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program - BioSpace
Lilly to invest $1.2bn in Puerto Rico manufacturing site - PMLiVE
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $930 to $1,038 - 富途牛牛
Street View: Eli Lilly's obesity drug pipeline seen powering sustained growth - TradingView
Dividend Roundup: Visa, Eli Lilly, Ford, Wells Fargo, and more - Seeking Alpha
Massive sales for weight loss drugs spur Eli Lilly’s Q3 - Pharmaceutical Technology
Morgan Stanley Adjusts Price Target on Eli Lilly to $1,069 From $1,023, Maintains Overweight Rating - MarketScreener
Weight-loss drug wars enter new phase as Eli Lilly goes global - Axios
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $951 From $879, Maintains Buy Rating - MarketScreener
Jefferies Adjusts Price Target on Eli Lilly and Co. to $976 From $905, Maintains Buy Rating - MarketScreener
Leerink Partners Adjusts PT on Eli Lilly and Co. to $886 From $715, Maintains Market Perform Rating - MarketScreener
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $985 From $925, Maintains Overweight Rating - MarketScreener
Eli Lilly’s Sterling Results Highlight Rival Novo Nordisk’s Fading Fortunes - The Daily Upside
Eli Lilly and NVIDIA Partner to Build Pharma’s Most Powerful AI Supercomputer - Global Cosmetics News
Eli Lilly stock price target raised to $976 by Jefferies on strong earnings - Investing.com
Analyst: Eli Lilly's growth worries Novo investors but may be a positive indicator for next week's financial results - medwatch.com
Eli Lilly (LLY) One-Off $5.1 Billion Loss Raises New Questions for Bullish Growth Narratives - simplywall.st
Is Eli Lilly and Company stock a buy before product launchesJuly 2025 Movers & Real-Time Volume Analysis - newser.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):